Concord Biotech Q3 FY26: revenue up 14% YoY, 9M PAT down 25%
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Smallcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone Q3 FY26 revenue rose 14% YoY to Rs 27,813 lakhs, but 9M FY26 revenue fell 5% to Rs 72,918 lakhs. Standalone Q3 PAT was Rs 6,778 lakhs (down 8.5% YoY), while 9M PAT dropped 25% to Rs 17,324 lakhs. Q3 EPS stood at Rs 6.48 versus Rs 7.08. An exceptional charge of Rs 327.54 lakhs was booked for new labour codes. Auditor BSR and Co. LLP issued an unmodified review opinion. Paritosh Trivedi appointed as new Company Secretary.
9M profit down sharply despite Q3 revenue growth, pointing to margin pressure. One-time labour code charge recognized. Watch for sustainability of recovery.